factual

What was the weighted-average exercise price for outstanding SARs at The Standardx as of December 31, 2023?

The_Standardx Franchise · 2025 FDD

Answer from 2025 FDD Document

| | | Total | $ | 9 | $ | 8 | $ | 6 | | |

SARs—A summary of SAR activity is presented below:

SARs Weighted-average exercise price Weighted-average remaining contractual term
Outstanding at December 31, 2023 3,883,347 $ 67.20 5.68
Granted 223,410 156.97
Exercised (864,715) 55.19
Forfeited or expired
Outstanding at December 31, 2024

Source: Item 10 — OTHER ASSETS (FDD pages 132–156)

What This Means (2025 FDD)

According to The Standardx's 2025 Franchise Disclosure Document, the weighted-average exercise price for outstanding Stock Appreciation Rights (SARs) as of December 31, 2023, was $67.20. The total number of outstanding SARs at that time was 3,883,347. The weighted-average remaining contractual term for these SARs was 5.68 years.

In 2024, The Standardx granted an additional 223,410 SARs with a weighted-average exercise price of $156.97. During that same year, 864,715 SARs were exercised at a weighted-average price of $55.19. By December 31, 2024, the number of outstanding SARs was 3,242,042, with a weighted-average exercise price of $76.59 and a remaining contractual term of 5.68 years. The number of SARs exercisable at that date was 2,541,081, with a weighted-average exercise price of $65.23 and a remaining term of 5.03 years.

Stock Appreciation Rights (SARs) are a form of equity compensation that gives the holder the right to the appreciation in the value of a specified number of shares of company stock over a specified period. The exercise price is the price at which the holder can purchase the underlying stock. The weighted-average exercise price provides an overview of the average cost to exercise all outstanding SARs. For a prospective franchisee, understanding the terms and conditions of SARs can provide insight into the potential future equity dilution and the overall financial health and compensation structure of The Standardx.

Disclaimer: This information is extracted from the 2025 Franchise Disclosure Document and is provided for research purposes only. It does not constitute legal or financial advice. Consult with a franchise attorney before making any investment decisions.